R Zarate

Summary

Affiliation: University of Navarra
Country: Spain

Publications

  1. pmc Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis
    R Zarate
    Laboratory of Pharmacogenomics, Division of Oncology, CIMA, University Clinic of Navarra, Avda Pio XII 36, Pamplona, Spain
    Br J Cancer 102:987-94. 2010
  2. ncbi request reprint Potential application of GSTT1-null genotype in predicting toxicity associated to 5-fluouracil irinotecan and leucovorin regimen in advanced stage colorectal cancer patients
    R Zárate Romero
    Laboratory of Biotechnology and Pharmacogenomics, Center for Applied Medical Research, University Clinic of Navarra, Navarra 31008, Spain
    Oncol Rep 16:497-503. 2006
  3. pmc Xeroderma pigmentosum group D 751 polymorphism as a predictive factor in resected gastric cancer treated with chemo-radiotherapy
    R N Zárate
    Laboratory of Biotechnology and Pharmacogenomics, University Clinic of Navarra, Pamplona 31008, Spain
    World J Gastroenterol 12:6032-6. 2006
  4. ncbi request reprint GSTP1 and MTHFR polymorphisms are related with toxicity in breast cancer adjuvant anthracycline-based treatment
    R Zarate
    Laboratory of Biotechnology, University Clinic of Navarra, Pamplona, Spain
    Curr Drug Metab 8:481-6. 2007
  5. doi request reprint A new mutation in the hMSH2 gene in a Spanish Lynch syndrome family
    Ruth Zarate
    Clinical Genetics Unit, University Clinic of Navarra, Pamplona, Navarra, Spain
    Clin Transl Oncol 12:849-51. 2010
  6. pmc Dose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients
    A Abajo
    Laboratory of Pharmacogenomics, Division of Oncology, Center for Applied Medical Research CIMA, University of Navarra, Pamplona, Spain
    Br J Cancer 103:1529-35. 2010
  7. doi request reprint Association of RRM1 -37A>C polymorphism with clinical outcome in colorectal cancer patients treated with gemcitabine-based chemotherapy
    J Rodriguez
    Department of Oncology, Clinic University of Navarra, Pamplona, Spain
    Eur J Cancer 47:839-47. 2011
  8. ncbi request reprint Pharmacogenomic analysis of the triplet combination of gemcitabine, oxaliplatin, and cetuximab as salvage therapy for metastatic colorectal cancer (mCRC) patients
    A Hernandez
    Clinica Universitaria de Navarra, Pamplona, Spain
    J Clin Oncol 27:e14531. 2009
  9. pmc Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients
    A Abajo
    Laboratory of Pharmacogenomics, Division of Oncology, Center for Applied Medical Research, University of Navarra, Pamplona, Spain
    Br J Cancer 107:287-90. 2012
  10. ncbi request reprint Triplet therapy with oxaliplatin, irinotecan and escalating doses of capecitabine in liver metastases from colorectal cancer patients
    M Ponz-Sarvise
    Clinica Universitaria Navarra, Pamplona, Spain Clínica Universitaria de Navarra, Pamplona, Spain
    J Clin Oncol 26:15020. 2008

Collaborators

Detail Information

Publications15

  1. pmc Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis
    R Zarate
    Laboratory of Pharmacogenomics, Division of Oncology, CIMA, University Clinic of Navarra, Avda Pio XII 36, Pamplona, Spain
    Br J Cancer 102:987-94. 2010
    ..A pharmacogenomic analysis was performed to investigate the association between SNPs and treatment outcome...
  2. ncbi request reprint Potential application of GSTT1-null genotype in predicting toxicity associated to 5-fluouracil irinotecan and leucovorin regimen in advanced stage colorectal cancer patients
    R Zárate Romero
    Laboratory of Biotechnology and Pharmacogenomics, Center for Applied Medical Research, University Clinic of Navarra, Navarra 31008, Spain
    Oncol Rep 16:497-503. 2006
    ..Our data suggest that GSTT1-null is associated with a greater probability of developing toxicity to 5-Fu/CPT-11/Lv treatments, indicating a potential application of this genetic analysis in predicting adverse effects of this regimen...
  3. pmc Xeroderma pigmentosum group D 751 polymorphism as a predictive factor in resected gastric cancer treated with chemo-radiotherapy
    R N Zárate
    Laboratory of Biotechnology and Pharmacogenomics, University Clinic of Navarra, Pamplona 31008, Spain
    World J Gastroenterol 12:6032-6. 2006
    ..To evaluate the potential association of xeroderma pigmentosum group D (XPD) codon 751 variant with outcome after chemo-radiotherapy in patients with resected gastric cancer...
  4. ncbi request reprint GSTP1 and MTHFR polymorphisms are related with toxicity in breast cancer adjuvant anthracycline-based treatment
    R Zarate
    Laboratory of Biotechnology, University Clinic of Navarra, Pamplona, Spain
    Curr Drug Metab 8:481-6. 2007
    ..3 to 254), P = 0.008. Our results suggest that GSTP1 and MTHFR genotypes may be consider relevant and independent factors of toxicity in adjuvant anthracycline-based treatment of breast cancer...
  5. doi request reprint A new mutation in the hMSH2 gene in a Spanish Lynch syndrome family
    Ruth Zarate
    Clinical Genetics Unit, University Clinic of Navarra, Pamplona, Navarra, Spain
    Clin Transl Oncol 12:849-51. 2010
    ..The mutation was not present in 116 normal controls screened. The medical implications for the carrier relatives are discussed...
  6. pmc Dose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients
    A Abajo
    Laboratory of Pharmacogenomics, Division of Oncology, Center for Applied Medical Research CIMA, University of Navarra, Pamplona, Spain
    Br J Cancer 103:1529-35. 2010
    ..Pharmacogenomic analysis was performed to investigate the association between VEGF single-nucleotide polymorphisms and clinical outcome...
  7. doi request reprint Association of RRM1 -37A>C polymorphism with clinical outcome in colorectal cancer patients treated with gemcitabine-based chemotherapy
    J Rodriguez
    Department of Oncology, Clinic University of Navarra, Pamplona, Spain
    Eur J Cancer 47:839-47. 2011
    ..To investigate whether single nucleotide polymorphisms (SNPs) in gemcitabine (GMB) metabolism genes were associated with clinical outcome in pre-treated metastatic colorectal cancer (mCRC) patients...
  8. ncbi request reprint Pharmacogenomic analysis of the triplet combination of gemcitabine, oxaliplatin, and cetuximab as salvage therapy for metastatic colorectal cancer (mCRC) patients
    A Hernandez
    Clinica Universitaria de Navarra, Pamplona, Spain
    J Clin Oncol 27:e14531. 2009
    ..We aimed to investigate whether germ line polymorphisms may be predictors of clinical outcome in mCRC pts treated with this combination...
  9. pmc Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients
    A Abajo
    Laboratory of Pharmacogenomics, Division of Oncology, Center for Applied Medical Research, University of Navarra, Pamplona, Spain
    Br J Cancer 107:287-90. 2012
    ..To identify whether circulating levels of angiogenesis-related factors may be predictive of bevacizumab efficacy in pre-treated metastatic colorectal cancer (mCRC) patients...
  10. ncbi request reprint Triplet therapy with oxaliplatin, irinotecan and escalating doses of capecitabine in liver metastases from colorectal cancer patients
    M Ponz-Sarvise
    Clinica Universitaria Navarra, Pamplona, Spain Clínica Universitaria de Navarra, Pamplona, Spain
    J Clin Oncol 26:15020. 2008
    ....
  11. ncbi request reprint Hepatic arterial infusion (HAI) of oxaliplatin combined with docetaxel and capecitabine in patients with liver metastases from non-colorectal gastrointestinal tumours: A dose-finding study
    A Hernandez
    Clinica Universitaria de Navarra, Pamplona, Spain
    J Clin Oncol 26:15666. 2008
    ....
  12. doi request reprint Epigenetic events in normal colonic mucosa surrounding colorectal cancer lesions
    N Ramirez
    Laboratory of Pharmacogenomics, Center for Applied Medical Research CIMA, University of Navarra, Pamplona, Spain
    Eur J Cancer 44:2689-95. 2008
    ..Our results indicate that epigenetic changes in mucosa surrounding colorectal neoplastic lesions may describe a 'field cancerisation' phenomenon that may occur previous to genetic alterations in early stages of carcinogenesis...
  13. pmc Combining chemotherapy and targeted therapies in metastatic colorectal cancer
    J Rodriguez
    Unit for the Research and Treatment of Gastrointestinal Malignancies, Department of Oncology, Clinica Universitaria, Center for Applied Medical Research, University of Navarra, Spain
    World J Gastroenterol 13:5867-76. 2007
    ..In this article we review various treatment options combining cytotoxic and targeted therapies currently available for patients with metastatic colorectal cancer...
  14. pmc Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues
    E Bandres
    Laboratory of Pharmacogenomics, Cancer Research Program Center for Applied Medical Research, University of Navarra, Navarra, Spain
    Mol Cancer 5:29. 2006
    ..In addition, the expression level of miR-31 was correlated with the stage of CRC tumor. Our results suggest that miRNA expression profile could have relevance to the biological and clinical behavior of colorectal neoplasia...
  15. ncbi request reprint Dose escalation of capecitabine in combination with biweekly cetuximab and hepatic arterial infusion (HAI) of oxaliplatin in patients with liver metastases of colorectal cancer: Preliminary clinical results
    A Viudez
    Clinica Universitaria de Navarra, Pamplona, Spain University of Navarra, Pamplona, Spain Clínica Universidad de Navarra, Pamplona, Spain
    J Clin Oncol 27:e15080. 2009
    ....